Impact of IL-2 on Treatment Tolerance in Patients With High-Risk Neuroblastoma Treated With Dinutuximab Beta-Based Immunotherapy

Patients with high-risk neuroblastoma treated with continuous long-term infusion of anti-GD2 antibody dinutuximab beta (DB) in combination with IL-2 show an acceptable safety profile. Here, we compared treatment tolerance with and without IL-2. Ninety-nine patients with high-risk neuroblastoma recei...

Descripción completa

Detalles Bibliográficos
Autores principales: Cicek, Filiz, Troschke-Meurer, Sascha, Ceylan, Kiraz, Jahns, Luciana J., Zumpe, Maxi, Siebert, Nikolai, Ehlert, Karoline, Lode, Holger N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772209/
https://www.ncbi.nlm.nih.gov/pubmed/33392114
http://dx.doi.org/10.3389/fped.2020.582820

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7772209/
https://www.ncbi.nlm.nih.gov/pubmed/33392114
http://dx.doi.org/10.3389/fped.2020.582820

Ejemplares similares